Briggs Morrison's Insider Trades & SAST Disclosures
Briggs Morrison's most recent trade in Carisma Therapeutics Inc was a trade of 19,350 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 26, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Briggs Morrison.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Carisma Therapeutics Inc | Briggs W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 19,350 | 19,350 | - | - | Stock Option (Right to Buy) | |
| Repare Therapeutics Inc | Briggs W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 27,200 | 27,200 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Briggs W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 9,070 | 9,070 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Briggs W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 5,899 | 29,996 (0%) | 0% | 0 | Common Stock | |
| Werewolf Therapeutics Inc | Briggs W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Syndax Pharmaceuticals Inc | W. Briggs Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 17,000 | 34,836 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.77 per share. | 09 Aug 2023 | 52,855 | 70,691 (0%) | 0% | 8.8 | 463,538 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2023 | 52,855 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director | Sale of securities on an exchange or to another person at price $ 18.27 per share. | 09 Aug 2023 | 52,855 | 17,836 (0%) | 0% | 18.3 | 965,402 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director | Sale of securities on an exchange or to another person at price $ 20.40 per share. | 10 Jul 2023 | 52,855 | 17,836 (0%) | 0% | 20.4 | 1,078,068 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2023 | 52,855 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.77 per share. | 10 Jul 2023 | 52,855 | 70,691 (0%) | 0% | 8.8 | 463,538 | Common Stock |
| Werewolf Therapeutics Inc | Briggs W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 13,200 | 13,200 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Briggs W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 12,787 | 12,787 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Briggs W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 4,121 | 24,097 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2023 | 28,273 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director | Sale of securities on an exchange or to another person at price $ 21.18 per share. | 09 Jun 2023 | 28,273 | 17,836 (0%) | 0% | 21.2 | 598,797 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.77 per share. | 09 Jun 2023 | 28,273 | 70,691 (0%) | 0% | 8.8 | 247,954 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2023 | 24,582 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director | Sale of securities on an exchange or to another person at price $ 21.18 per share. | 09 Jun 2023 | 24,582 | 46,109 (0%) | 0% | 21.2 | 520,625 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.38 per share. | 09 Jun 2023 | 24,582 | 42,418 (0%) | 0% | 6.4 | 156,833 | Common Stock |
| Repare Therapeutics Inc | Briggs W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 27,200 | 27,200 | - | - | Stock Option (right to buy) | |
| Carisma Therapeutics Inc | Briggs W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 38,700 | 38,700 | - | - | Stock Option (Right to Buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.38 per share. | 09 May 2023 | 52,855 | 70,691 (0%) | 0% | 6.4 | 337,215 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director | Sale of securities on an exchange or to another person at price $ 21.41 per share. | 09 May 2023 | 52,855 | 17,836 (0%) | 0% | 21.4 | 1,131,478 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2023 | 52,855 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director | Sale of securities on an exchange or to another person at price $ 19.53 per share. | 10 Apr 2023 | 52,855 | 17,836 (0%) | 0% | 19.5 | 1,032,237 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.38 per share. | 10 Apr 2023 | 52,855 | 70,691 (0%) | 0% | 6.4 | 337,215 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2023 | 52,855 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.38 per share. | 13 Mar 2023 | 52,854 | 70,690 (0%) | 0% | 6.4 | 337,209 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Sale of securities on an exchange or to another person at price $ 22.53 per share. | 13 Mar 2023 | 52,854 | 17,836 (0%) | 0% | 22.5 | 1,190,674 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2023 | 52,854 | 0 | - | - | Stock Option (Right to Buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.38 per share. | 06 Feb 2023 | 52,854 | 70,690 (0%) | 0% | 6.4 | 337,209 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2023 | 52,854 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Sale of securities on an exchange or to another person at price $ 26.83 per share. | 06 Feb 2023 | 52,854 | 17,836 (0%) | 0% | 26.8 | 1,417,909 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 32,000 | 32,000 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Sale of securities on an exchange or to another person at price $ 23.03 per share. | 19 Sep 2022 | 114,339 | 17,836 (0%) | 0% | 23.0 | 2,633,044 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2022 | 114,339 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.90 per share. | 19 Sep 2022 | 114,339 | 132,175 (0%) | 0% | 10.9 | 1,246,295 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2022 | 59,649 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Sale of securities on an exchange or to another person at price $ 23.25 per share. | 19 Sep 2022 | 59,649 | 17,836 (0%) | 0% | 23.3 | 1,387,012 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.90 per share. | 19 Sep 2022 | 59,649 | 77,485 (0%) | 0% | 10.9 | 650,174 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Sale of securities on an exchange or to another person at price $ 23.80 per share. | 14 Sep 2022 | 87,645 | 17,836 (0%) | 0% | 23.8 | 2,085,855 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 14 Sep 2022 | 87,645 | 105,481 (0%) | 0% | 7.2 | 631,044 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2022 | 87,645 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 14 Sep 2022 | 71,966 | 89,802 (0%) | 0% | 7.2 | 518,155 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Sale of securities on an exchange or to another person at price $ 23.22 per share. | 14 Sep 2022 | 71,966 | 17,836 (0%) | 0% | 23.2 | 1,671,015 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2022 | 71,966 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 14 Sep 2022 | 66,775 | 84,611 (0%) | 0% | 7.2 | 480,780 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Sale of securities on an exchange or to another person at price $ 24.20 per share. | 14 Sep 2022 | 66,775 | 17,836 (0%) | 0% | 24.2 | 1,616,035 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2022 | 66,775 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.90 per share. | 14 Sep 2022 | 53,034 | 70,870 (0%) | 0% | 10.9 | 578,071 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Sale of securities on an exchange or to another person at price $ 23.22 per share. | 14 Sep 2022 | 53,034 | 17,836 (0%) | 0% | 23.2 | 1,231,423 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2022 | 53,034 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2022 | 62,292 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Sale of securities on an exchange or to another person at price $ 19.00 per share. | 01 Jul 2022 | 62,292 | 17,836 (0%) | 0% | 19.0 | 1,183,430 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 01 Jul 2022 | 62,292 | 80,128 (0%) | 0% | 7.2 | 448,502 | Common Stock |
| Arvinas Inc | Briggs W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 10,192 | 10,192 | - | - | Stock Option (right to buy) | |
| Werewolf Therapeutics Inc | Briggs W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 11,600 | 11,600 | - | - | Stock Option (right to buy) | |
| Repare Therapeutics Inc | Briggs W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 49,000 | 49,000 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Briggs W. Morrison | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 14 Apr 2022 | 16,188 | 40,936 (0%) | 0% | 16 | 259,008 | Common Stock |
| Arvinas Inc | Briggs W. Morrison | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2022 | 16,188 | 494 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Briggs W. Morrison | Director | Sale of securities on an exchange or to another person at price $ 67.03 per share. | 14 Apr 2022 | 10,754 | 19,976 (0%) | 0% | 67.0 | 720,888 | Common Stock |
| Arvinas Inc | Briggs W. Morrison | Director | Sale of securities on an exchange or to another person at price $ 66.07 per share. | 14 Apr 2022 | 7,104 | 30,730 (0%) | 0% | 66.1 | 469,356 | Common Stock |
| Arvinas Inc | Briggs W. Morrison | Director | Sale of securities on an exchange or to another person at price $ 65.24 per share. | 14 Apr 2022 | 3,102 | 37,834 (0%) | 0% | 65.2 | 202,372 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 01 Apr 2022 | 70,545 | 88,381 (0%) | 0% | 7.2 | 507,924 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 70,545 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 3,128 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 01 Apr 2022 | 3,128 | 20,964 (0%) | 0% | 7.2 | 22,522 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs W. Morrison | Director, President, Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 160,000 | 160,000 | - | - | Stock Options (Right to buy) | |
| Arvinas Inc | Briggs W. Morrison | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 14 Jan 2022 | 16,188 | 45,708 (0%) | 0% | 16 | 259,008 | Common Stock |
| Arvinas Inc | Briggs W. Morrison | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 16,188 | 16,682 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Briggs W. Morrison | Director | Sale of securities on an exchange or to another person at price $ 64.33 per share. | 14 Jan 2022 | 9,919 | 35,789 (0%) | 0% | 64.3 | 638,109 | Common Stock |
| Arvinas Inc | Briggs W. Morrison | Director | Sale of securities on an exchange or to another person at price $ 67.28 per share. | 14 Jan 2022 | 5,100 | 26,856 (0%) | 0% | 67.3 | 343,144 | Common Stock |
| Arvinas Inc | Briggs W. Morrison | Director | Sale of securities on an exchange or to another person at price $ 65.24 per share. | 14 Jan 2022 | 3,833 | 31,956 (0%) | 0% | 65.2 | 250,071 | Common Stock |
| Arvinas Inc | Briggs W. Morrison | Director | Sale of securities on an exchange or to another person at price $ 67.69 per share. | 14 Jan 2022 | 2,108 | 24,748 (0%) | 0% | 67.7 | 142,696 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.90 per share. | 17 Dec 2021 | 35,156 | 83,492 (0%) | 0% | 10.9 | 383,200 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2021 | 35,156 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 17 Dec 2021 | 35,156 | 48,336 (0%) | 0% | 20 | 703,120 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2021 | 70,262 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 17 Sep 2021 | 70,262 | 118,598 (0%) | 0% | 7.2 | 505,886 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.07 per share. | 17 Sep 2021 | 70,262 | 48,336 (0%) | 0% | 20.1 | 1,410,018 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 17 Sep 2021 | 50 | 48,336 (0%) | 0% | 20 | 1,000 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2021 | 50 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 17 Sep 2021 | 50 | 48,386 (0%) | 0% | 7.2 | 360 | Common Stock |
| Arvinas Inc | Briggs Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 7,511 | 7,511 | - | - | Stock Option (right to buy) | |
| Repare Therapeutics Inc | Briggs Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2021 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Werewolf Therapeutics Inc | Briggs W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 23,200 | 23,200 | - | - | Stock Option (right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.55 per share. | 08 Feb 2021 | 35,156 | 48,336 (0%) | 0% | 20.5 | 722,403 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 08 Feb 2021 | 35,156 | 83,492 (0%) | 0% | 7.2 | 253,123 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2021 | 35,156 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 195,000 | 195,000 | - | - | Stock Option (Right to Buy) | |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Other type of transaction at price $ 12.00 per share. | 03 Feb 2021 | 1,771 | 48,336 (0%) | 0% | 12 | 21,252 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.04 per share. | 09 Nov 2020 | 62,938 | 46,565 (0%) | 0% | 20.0 | 1,261,265 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2020 | 62,938 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 09 Nov 2020 | 62,938 | 109,503 (0%) | 0% | 7.2 | 453,154 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2020 | 17,466 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.06 per share. | 09 Nov 2020 | 17,466 | 46,565 (0%) | 0% | 20.1 | 350,312 | Common Stock |
| Syndax Pharmaceuticals Inc | Briggs Morrison | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 09 Nov 2020 | 17,466 | 64,031 (0%) | 0% | 7.2 | 125,755 | Common Stock |
| Repare Therapeutics Inc | Briggs Morrison | Director | Purchase of securities on an exchange or from another person at price $ 20.00 per share. | 23 Jun 2020 | 4,800 | 4,800 | - | 20 | 96,000 | Common Shares |
| Nextcure Inc | Briggs Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 14,250 | 14,250 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges